GlassScriptPhysician profile
Jack Moore Whitehead
NPI 1952834558
$2,512.19
in general payments reported to CMS, 2019-2025
21 companies · $155 in 2025
The $155 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.54 · 2020: $27.58 · 2021: $394 · 2022: $877 · 2023: $861 · 2024: $122 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $487.44 | 2020-2025 | Dyanavel Xr |
| Corium, LLC | $460.15 | 2022-2023 | Azstarys |
| Pfizer INC. | $218.49 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $218.04 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $165.64 | 2022-2024 | Bexsero, Pediarix |
| Takeda Pharmaceuticals U.S.A., INC. | $156.77 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $154.65 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Ironshore Pharmaceuticals INC. | $109.56 | 2023 | Jornay Pm |
| Alexion Pharmaceuticals, INC. | $91.01 | 2019-2022 | |
| Sanofi Pasteur INC. | $73.64 | 2021-2023 | |
| Adlon Therapeutics L.P. | $64.92 | 2021 | |
| Seqirus USA INC | $46.85 | 2022-2024 | Flucelvax Quadrivalent, Flucelvax |
| Neos Therapeutics, LP | $45.79 | 2022 | |
| Lnhc, INC | $43.71 | 2025 | Zelsuvmi |
| Astrazeneca Pharmaceuticals LP | $43.54 | 2023-2024 | Flumist Quadrivalent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $29.15 | 2021-2022 | |
| Kaleo, INC. | $27.30 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.89 | 2024 | |
| Verrica Pharmaceuticals INC. | $18.98 | 2024 | Ycanth |
| Organon LLC | $18.95 | 2023 | Nexplanon |
| Neurelis, INC. | $13.72 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.